HomeAI · summaries
Storia in 17 fonti
Daraxonrasib offers ‘transformational’ benefit in metastatic pancreatic cancer
CHICAGO — The eagerly awaited full dataset from arguably the most pivotal pancreatic cancer trial in decades is now public.Based on the buzz it created among ASCO Annual Meeting attendees, the benefits observed with daraxonrasib among pretreated individuals with metastatic disease exceeded already-lofty expectations.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
pbs.org
Pancreatic cancer is deadly and difficult to treat. A new pill could change that
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.
- ·
biopharmadive.com
‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer
Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.
